

FACT SHEET

RECCE PHARMACEUTICALS LTD (ASX:RCE, FSE:R9Q)

JUNE 2025



An Emerging Global Leader in a New Generation of Anti-Infectives

Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) is an Australian clinical stage biotech company engaged in the development and commercialisation of a new class of Synthetic Anti-infectives designed to address the urgent global health problem of antibiotic-resistant superbugs.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: **RECCE® 327** as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; **RECCE® 435** as an orally-administered therapy for bacterial infections; and **RECCE® 529** for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the hypercellular mutation of bacteria - the challenge of all existing antibiotics to date.

Sepsis affects **50 million people worldwide** a year. There are currently **no drug therapies** specifically for the treatment of severe sepsis and it is by far the **most expensive condition** treated in US hospitals.

The FDA has awarded RECCE® 327 **Qualified Infectious Disease Product** designation under the Generating Antibiotic Initiatives Now (GAIN) Act - labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has also been included on **The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the only synthetic polymer and sepsis drug candidate in development.**

Recce wholly owns its automated manufacturing, ready to support human clinical trials. Recce's anti-infective pipeline seeks to exploit the unique capabilities of RECCE® technologies targeting synergistic, unmet medical needs.

Corporate Summary

- Proprietary New Class of Anti-Infectives against bacteria and viruses, protected by Composition of Matter Patent
- World's Most Clinically Advanced New Class of Anti-Infectives** focussed upon the urgent global health threat of antibiotic-resistant superbugs
- Multiple Clinical Trials Complete, others underway - **Broad spectrum therapeutic potential for major unmet medical needs of Sepsis/Urosepsis, Burn Wound Infections, ABSSSIs, Diabetic Foot Infections and more**
- R327 bactericidal activity against all six ESKAPE pathogens
- Unique Mechanism of Action - R327 does not succumb to antimicrobial mutation (superbugs) - fundamental challenge of all existing antibiotics to date. It works fast and keeps on working with repeated use
- R327 cleared for use under Therapeutic Goods Administration (TGA) Special Access Scheme - Category A
- R327 included in **The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the only synthetic polymer and sepsis drug candidate in development. The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens**, recognising Recce's efforts to combat antimicrobial resistance.
- Clinical Phase I-II and preclinical product produced at RECCE Macquarie Park facility in Australia. GMP Manufacturing facility in Australia for Phase III/Scale up
- Australian Government awarded **AUD \$54,947,284 (USD \$37,043,433) Advanced Overseas Finding*** across RCE infectious disease portfolio*

SNAP SHOT

Ticker	ASX:RCE, FSE:R9Q
Date listed	January 2016, March 2021
52 week range	AUD \$0.2750 - A\$0.6200
Market Cap	AUD \$80m (priced at \$0.3250)
Cash balance*	A\$16m
Shares on issue	262m
3 month avg. vol	224.74K (per trading day)
Sector	Pharmaceuticals, Biotechnology & Life Sciences

*The Company has raised a total of approximately A\$8.4 million through existing shareholders and now goes to the wider market for the remainder A\$7.4m which it expects to place at the same price in near weeks.

Recce expects a pro-forma cash position post the Offer of -A\$16.0 million (before offer costs).

BOARD AND MANAGEMENT

Dr John Prendergast	Executive Chairman
James Graham	Managing Director & Chief Executive Officer
Michele Dilizia	Executive Director & Chief Scientific Officer
Dr Justin Ward	Executive Director & Principal Quality Chemist
Dr Alan W Dunton	Chief Medical Advisor & Non-Executive Director
Alistair McKeough	Non-Executive Director
Arthur Kollaras	Head of Manufacturing
Justin Reynolds	CFO (Outsourced - Pitcher Partners Sydney)
Maggie Niewidok	Company Secretary (Outsourced - Kardos Scanlan)

PATENT PORTFOLIO

Patents covering the manufacturing process run until 2029. Granted provisional patents covering additional modes of delivery and anti-viral uses, run until 2037.

Recce Pharmaceuticals Ltd patent portfolio has continued to strengthen with granted patents in key pharmaceutical markets such as USA, Europe, Japan, China and Australia.

FILED	PATENT FAMILY 1	EXPIRY	PATENT FAMILY 2	EXPIRY	PATENT FAMILY 3	EXPIRY
Australia	✓	2028	✓	2037	✓	2037
USA	✓	2029	✓	2037	✓	2037
Europe	✓	2028	✓	2037	✓	2037
Germany	✓	2028	✓	2037	✓	2037
Spain	✓	2028	✓	2037	✓	2037
France	✓	2029	✓	2037	✓	2037
UK	✓	2028	✓	2037	✓	2037
Italy	✓	2028	✓	2037	✓	2037
Sweden	✓	2028	✓	2037	✓	2037
Japan	✓	2028	✓	2037	✓	2037
China	✓	2028	✓	2037	✓	2037
HK	Pending	2028	Pending	2037	✓	2037

Patent Family 1 - **Granted**

Unique and highly economical manufacturing process

Patent Family 2 - **Pending/Granted**

Applications (Multi-drug delivery)

Patent Family 3 - **Granted**

Anti-viral use

Patent Family 4 - **Pending/Granted**

Process for Preparation of Biologically Active Copolymer (**Australia Granted**, other Patent Cooperation Treaty countries **pending/allowed**)

Efficacy - RECCE® 327

- 99.9% effective against full suite of ESKAPE pathogens including Multidrug-Resistant forms
- Acts against bacteria in both normal and mutated superbug forms
- Multiple tests demonstrate efficacy against Gram-positive and Gram-negative including their superbug forms
- *In-vitro* studies of RECCE® 327 demonstrate a faster kill rate than existing antibiotics
- Contains a patented polymeric structure, intentionally designed to overcome the traditional challenges of bacterial mutation/resistance
- *In-vivo* studies against SARS-CoV-2 (COVID-19) and influenza virus

Safety - RECCE® 327


- Data review showed both methods of administration, I.V. and Gel, of multiple RECCE®327 clinical trials **to be safe & well tolerated - no serious adverse events**
- Multiple studies of mutagenicity (cancer) are clear
- Numerous studies to date indicate the safety of RECCE® 327
- Is suited to administration against sepsis by intravenous drip
- Indicates a safe therapeutic dosing window over multiple time stamps

RECCE® 327 Mechanism of Action




Stage 1

RECCE 327 targets and irreversibly bind to essential bacterial proteins



Stage 2

RECCE 327 disrupts bacterial metabolism and depletes ATP at the cell surface



Stage 3


RECCE 327 kills bacteria rapidly without inducing cell lysis



Stage 4

RECCE 327 is rapidly and irreversibly bactericidal

RECCE® Multiple Anti-Infective Applications



World Health Organisation (WHO) List of Most Threatening Antibiotic-Resistant Bacteria

The WHO published a priority list of 12 antibiotic-resistant bacteria*.

PRIORITY 1: CRITICAL	RECCE® 327
<i>Pseudomonas aeruginosa</i> , carbapenem-resistant	✓ 1
<i>Enterobacteriaceae</i> , carbapenem-resistant, ESBL-producing	✓ 2
<i>Acinetobacter baumannii</i> , carbapenem-resistant	✓ 3
<i>Mycobacterium tuberculosis</i> , rifampicin-resistant	NOT TESTED
PRIORITY 2: HIGH	
<i>Enterococcus faecium</i> , vancomycin-resistant	✓ 4
<i>Staphylococcus aureus</i> , methicillin-resistant	✓ 5
<i>Neisseria gonorrhoeae</i> , cephalosporin-resistant, fluoroquinolone-resistant	✓ 6
<i>Campylobacter spp.</i> , fluoroquinolone-resistant	NOT TESTED
<i>Salmonellae</i> , fluoroquinolone-resistant	NOT TESTED
<i>Shigella spp.</i> , fluoroquinolone-resistant	NOT TESTED
PRIORITY 3: MEDIUM	
<i>Streptococcus pneumoniae</i> , macrolide-resistant	✓ 7
<i>Haemophilus influenzae</i> , ampicillin-resistant	NOT TESTED
Group A <i>Streptococci</i> , macrolide-resistant	✓ 8
Group B <i>Streptococci</i> , penicillin-resistant	✓ 9

- 1 Active *in vitro* against Recce's own superbug of this bacterium
 - 2 Active *in vivo* against a member of this family CRE *E. coli*
 - 3 Active *in vitro* and against superbug variant CRAB
 - 4 Active *in vitro* against a very closely related species, *Enterococcus faecalis*
 - 5 Active both *in vitro* and *in vivo* against MRSA, Methicillin-resistant *S. aureus*
 - 6 Active *in vitro* (superbug not available)
 - 7 Active *in vitro* against related superbug *Klebsiella pneumoniae*
 - 8 Active *in-vitro* against *Streptococcus pyogenes*
 - 9 Active *in-vitro* against a very closely related species, *Streptococcus pyogenes*
- * List as of 2024



Sydney – Head Office

Level 15, 1 Farrer Place
Governor Macquarie Tower
Sydney NSW 2000
Australia

Macquarie Park – Production

Unit 8, 64 Talvera Road
Macquarie Park NSW 2113
Australia

Perth – R&D Centre

Suite 10, 3 Brodie Hall Drive
Technology Park
Bentley WA 6102
Australia

North America – Operations

Suite 1025
1717 Pennsylvania Avenue
Washington DC 20006
USA